GSK To Increase Its Investment In Asia

Multinational drugmaker GlaxoSmithKline (GSK) is looking to invest in small- and medium-sized pharmaceutical and biotechnology companies in Japan, reinforcing the company's strategic priority - to grow a diversified global business via an aggressive push into the emerging markets. According to BMI's inaugural Pharmaceutical Emerging Markets Sales Index (PEMSI), GSK's emerging market sales increased faster than any other drugmaker in 2008 and 2009. The firm's overall revenue grew from US$3,142mn in 2007 to US$3,795mn in 2008 - an increase of 20.8%. Revenue in emerging markets grew by 16% to US$9.25bn in

To read the full article, please choose one of the following options: